DISCLAIMER: This news article is a direct translation of the original Korean article from Pharm News. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.- Bionote USA attends 'WVC 2023', the largest veterinary conference held in the US- Focus on Veterinary Diagnostic Analyzers such as Vcheck F and Vcheck MLeading global biological raw material and animal diagnostics company BIONOTE is continuing its efforts to expand further into the US market.Bionote announced on the 28th, that its US Branch, BIONOTE USA (established in 2019), participated in the 'Western Veterinary Conference 2023' ("WVC") held in Las Vegas, NV, from the 19th of February to the 22nd of February and carried out extensive promotional and marketing activities.WVC is the largest veterinary conference, in terms of scale, held in the US and veterinary experts as well as companies from around the world meet to share their insight, latest innovations in animal related products/services.According to Bionote, their US counterpart actively promoted their Vcheck F immunodiagnostic analyzers (V200, V2400), as well as the newly developed equine progesterone, SAA and IgG biomarkers, at the event.Furthermore, BIONOTE USA also promoted the newly released POC molecular diagnostic analyzer, Vcheck M, which is capable of nucleic acid amplification and quantitative analysis for the detection and diagnosis of major infectious diseases. Vcheck M is intuitive to use, even without much training, for performing PCR on site with the results being ready within only 1 hour, explained Bionote.A Bionote spokesperson said, "We plan on continuing our marketing and promotional activities in future conferences and events" and that "Bionote will continue to expand our market share by introducing our molecular diagnostic products and clinical chemistry products along with our usual immunodiagnostic products, showcasing our diverse product portfolio to the global market".Link to original article: https://www.pharmnews.com/news/articleView.html?idxno=219272
- Carried out 16.5 million USD capital investment in addition to the 7.8 million USD invested last year - Business diversification through joint development of therapeutic antibody Bionote announced on the 8th of February, that they have entered into a contract with therapeutic antibody development company, Centenaire Biosciences ("Centenaire"), through which Bionote invested 16.5 million USD as capital investment. The total investment amount amounts to 24.3 million USD, including the 7.8 million USD invested last year along with SD Investment. The total share held increased from 9.09% to 27%. Bionote plans to continue their ongoing partnership with Centenaire through this investment, especially in co-developing new therapeutic antibody pipelines. Centenaire is a sister company of Meditox, founded in 2021. They have been developing treatments for cancer, autoimmune diseases, and nervous system diseases through their innovative antibody platform technology. CTN001, which has been shown to be greatly effective for HER2 low-expression cancer has especially great market potential as the HER2 accounts for over 50% of breast cancers. The two companies are planning for the clinical trials of the CTN001 product, signing a contract with Samsung Biologics and developing the process for the manufacture of clinical samples. Furthermore, the two companies are also cooperating in the development of new treatments for non-small cell lung cancer and acute myeloid leukemia as well as cancer immunotherapy amongst various next generation anti-cancer treatments, expanding their research further. Dr. Byung Ki Cho, CEO of Bionote, commented that "We will strive to develop new, revolutionary therapeutic antibodies through our unrivaled antibody, antigen technology, coupled with the R&D capabilities of our company, which will synergize with Centenaire's innovative antibody platform technology". Ki Hyeok Yang, CEO of Centenaire, also commented that they would like to "Thank Bionote for trusting in the technology and development capabilities of Centenaire, continuing to invest large amounts in both 2022 and 2023." and added that "Centenaire will grow to be a game changer in the market by continuing to develop our own, original, products through our antibody platform technology, in a market full of new innovation, such as cancer immunotherapy, antibody-drug conjugates and T-cell engagers.
DISCLAIMER: This news article is a direct translation of the original Korean article from Korea Business TV. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.Bionote, an in vitro diagnostic product manufacturer, announced on the 23rd that they will be expanding into the clinical chemisry market, which is expected to grow to 1.25 billion USD by 2026.Bionote also announced that they are in the process of applying for approval of domestic and international sale of their clinical chemistry analyzer 'Vcheck C' and that they will start the approval process by January.This new product is capable of testing up to 4 samples at once, taking only 10 minutes on average, for quantitative detection of proteins, enzymes, amylase, etc. in the patient's blood samples, in order to give the veterinarian a general idea of the health of the patient in question, without sending the samples to a lab to get tested. everything can be performed on-site using this POC Clinical Chemistry Analyzer.The Clinical Chemistry market is currently valued at 768.6 million USD, and is expected to expand up to 1.25 billion USD by 2026.Bionote's CEO, DVM Byeong-Ki Cho, stated that "Bionote will provide a total diagnostic solution in the veterinary field through our Rapid, ELISA, Fluorescent immunoassay and POC Molecular Diagnostic devices as well as our new Clinical Chemistry analyzer, further improving our position as one of the global leaders in the veterinary field"Link to original article: https://www.wowtv.co.kr/NewsCenter/News/Read?articleId=A202212230095&t=NN